These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

777 related articles for article (PubMed ID: 27423335)

  • 1. Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.
    Chen C; Lü JM; Yao Q
    Med Sci Monit; 2016 Jul; 22():2501-12. PubMed ID: 27423335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Oxidative Stress in Hyperuricemia and Xanthine Oxidoreductase (XOR) Inhibitors.
    Liu N; Xu H; Sun Q; Yu X; Chen W; Wei H; Jiang J; Xu Y; Lu W
    Oxid Med Cell Longev; 2021; 2021():1470380. PubMed ID: 33854690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Xanthine oxidoreductase and its inhibitors: relevance for gout.
    Day RO; Kamel B; Kannangara DR; Williams KM; Graham GG
    Clin Sci (Lond); 2016 Dec; 130(23):2167-2180. PubMed ID: 27798228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a novel xanthine oxidoreductase inhibitor for hyperuricemia treatment with high efficacy and safety profile.
    Li X; Chen D; Qi C; Yang Y; Guo K; Ma C; Tian J; Li J; Zhang L; Wang B; Xiao Z; Ye F
    Biomed Pharmacother; 2024 Sep; 178():117223. PubMed ID: 39094541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic insights into xanthine oxidoreductase from development studies of candidate drugs to treat hyperuricemia and gout.
    Nishino T; Okamoto K
    J Biol Inorg Chem; 2015 Mar; 20(2):195-207. PubMed ID: 25501928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity.
    Furuhashi M
    Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E827-E834. PubMed ID: 32893671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The double faced role of xanthine oxidoreductase in cancer.
    Chen MM; Meng LH
    Acta Pharmacol Sin; 2022 Jul; 43(7):1623-1632. PubMed ID: 34811515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced XOR activity in eNOS-deficient mice: Effects on the nitrate-nitrite-NO pathway and ROS homeostasis.
    Peleli M; Zollbrecht C; Montenegro MF; Hezel M; Zhong J; Persson EG; Holmdahl R; Weitzberg E; Lundberg JO; Carlström M
    Free Radic Biol Med; 2016 Oct; 99():472-484. PubMed ID: 27609225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic kidney disease: Which role for xanthine oxidoreductase activity and products?
    Polito L; Bortolotti M; Battelli MG; Bolognesi A
    Pharmacol Res; 2022 Oct; 184():106407. PubMed ID: 35995347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
    Ernst ME; Fravel MA
    Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Inhibitors of xanthine oxidoreductase].
    Okamoto K
    Nihon Rinsho; 2008 Apr; 66(4):748-53. PubMed ID: 18409526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of new drug-like compounds from millets as Xanthine oxidoreductase inhibitors for treatment of Hyperuricemia: A molecular docking and simulation study.
    Pathak RK; Gupta A; Shukla R; Baunthiyal M
    Comput Biol Chem; 2018 Oct; 76():32-41. PubMed ID: 29906649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Xanthine Oxidoreductase Inhibitors.
    Vickneson K; George J
    Handb Exp Pharmacol; 2021; 264():205-228. PubMed ID: 32789757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allopurinol, an inhibitor of uric acid synthesis--can it be used for the treatment of metabolic syndrome and related disorders?
    Suzuki I; Yamauchi T; Onuma M; Nozaki S
    Drugs Today (Barc); 2009 May; 45(5):363-78. PubMed ID: 19584965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Xanthine Oxidase and its Role as Target in Cardiovascular Disease: Cardiovascular Protection by Enzyme Inhibition?
    Schuchardt M; Herrmann J; Tolle M; van der Giet M
    Curr Pharm Des; 2017; 23(23):3391-3404. PubMed ID: 28413972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibiting PNP for the therapy of hyperuricemia in Lesch-Nyhan disease: Preliminary in vitro studies with analogues of immucillin-G.
    Jacomelli G; Baldini E; Mugnaini C; Micheli V; Bernardini G; Santucci A
    J Inherit Metab Dis; 2019 Jan; 42(1):178-185. PubMed ID: 30740729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of xanthine oxidoreductase and uric acid in metabolic syndrome.
    Battelli MG; Bortolotti M; Polito L; Bolognesi A
    Biochim Biophys Acta Mol Basis Dis; 2018 Aug; 1864(8):2557-2565. PubMed ID: 29733945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia.
    Bove M; Cicero AF; Veronesi M; Borghi C
    Vasc Health Risk Manag; 2017; 13():23-28. PubMed ID: 28223818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The treatment of hyperuricemia.
    Gliozzi M; Malara N; Muscoli S; Mollace V
    Int J Cardiol; 2016 Jun; 213():23-7. PubMed ID: 26320372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dispelling dogma and misconceptions regarding the most pharmacologically targetable source of reactive species in inflammatory disease, xanthine oxidoreductase.
    Kelley EE
    Arch Toxicol; 2015 Aug; 89(8):1193-207. PubMed ID: 25995007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.